Genmab (GMAB) AGM 2022 summary
Event summary combining transcript, slides, and related documents.
AGM 2022 summary
26 Oct, 2026Opening remarks and agenda
Chair Deirdre P. Connelly reported on the prior year; CEO Jan van de Winkel presented 2022 plans, and CFO Anthony Pagano presented the auditor-endorsed FY2021 annual report.
Financial performance review
FY2021 annual report approved; DKK 3,008 million profit transferred to retained earnings.
Board and executive committee updates
Elizabeth O’Farrell elected to the board for a one-year term; Deirdre P. Connelly, Pernille Erenbjerg, Rolf Hoffmann, Paolo Paoletti and Anders Gersel Pedersen re-elected for one-year terms.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Genmab
- DKK 2,166 million of 2019 profit was retained as key AGM resolutions passed.GMAB
AGM 2020 - FY2020 results approved; directors re-elected and governance, remuneration and capital proposals passed.GMABAGM 2021
- AGM approved the 2022 accounts and adopted board, remuneration and treasury-share proposals.GMABAGM 2023
- 2023 accounts approved; directors re-elected and governance and capital proposals adopted.GMABAGM 2024
- Rina-S significantly improved PFS and OS in Phase 3 platinum-resistant ovarian cancer trial.GMABStudy result
- AbbVie collaboration pairs three bispecific programs with up to four discovery candidates.GMABCollaboration
- Proposed 2026 board pay combines cash fees, RSUs and committee meeting payments.GMABEGM 2026 presentation
- Pivotal phase III oncology readouts in Q4 2026 set up three major launches in 2027.GMABBank of America Global Healthcare Conference
- Rina-S® showed durable activity in gynecologic cancers, advancing toward Phase 3.GMABR&D Update